Prostate stem cell antigen is overexpressed in human transitional cell carcinoma.

Area of Science:

• Urothelial Carcinomas
• Cancer Immunotherapy
• Molecular Oncology

Background:

• Prostate stem cell antigen (PSCA) is expressed in prostate cancer and normal bladder.
• PSCA's role in transitional cell carcinoma (TCC) is not fully understood.
• Assessing PSCA expression is crucial for its potential as an immunotherapeutic target in bladder cancer.

Purpose of the Study:

• To compare PSCA expression in normal and malignant urothelial tissues.
• To evaluate PSCA as a potential immunotherapeutic target for transitional cell carcinoma (TCC).

Main Methods:

• Immunohistochemical analysis of PSCA protein expression in 32 normal bladders and 110 TCC specimens (dysplasia, CIS, STCC, ITCC, metastases).
• Semi-quantitative scoring of PSCA staining intensity and frequency.
• Examination of PSCA mRNA expression using Northern blot.
• Confocal microscopy to determine PSCA localization.

Main Results:

• PSCA expression was weak in normal bladder epithelium, primarily in superficial cells.
• Significantly higher and more uniform PSCA staining in carcinoma in situ (CIS) and superficial TCC (STCC) compared to normal bladder (P < 0.001).
• PSCA detected in 65% of muscle-invasive TCC (ITCC) and 57% of metastatic cancers, with higher expression correlating with increased tumor grade (P < 0.001).

Conclusions:

• PSCA is overexpressed in a majority of human TCCs, particularly CIS and superficial tumors.
• PSCA is localized to the cell surface in TCC.
• PSCA represents a promising target for bladder cancer diagnosis and therapy.